503A vs 503B compounding: what the difference means for GLP-1 drugs
The short answer
The 503A vs 503B compounding pharmacy difference comes down to oversight and quality rules. A 503A compounder is a state-licensed pharmacy or physician making a drug for one patient from a prescription, overseen mainly by a state board of pharmacy. A 503B outsourcing facility registers with FDA and must meet CGMP requirements. FDA has said semaglutide and tirzepatide are not on the 503B bulks list or the shortage list.
Key takeaways
- Neither 503A nor 503B makes a compounded drug FDA-approved.
- A 503A product must be compounded for you from a prescription written for you.
- A 503B facility is registered with FDA, but FDA says it does not approve or license any facility.
- FDA says semaglutide and tirzepatide are on neither the 503B bulks list nor the shortage list.
- Ask where a product is made, and check the license on the pharmacy verification page.
On this page
- 503A: state-licensed pharmacies and physicians
- 503B: outsourcing facilities
- The copy rule works differently under each section
- The bulk substance rule applies to 503B
- How the shortage wind-down treated each type
- The 2026 proposal on the 503B bulks list
- What this means if you’re a patient
- Frequently asked questions
- Sources
“503A” and “503B” are section numbers in the Federal Food, Drug, and Cosmetic Act. Each one describes a legal route for compounding a drug, with its own regulator, its own quality standards and its own limits. If you’re trying to make sense of a compounded semaglutide or tirzepatide product, knowing which route it came through tells you which rules applied to it.
Neither route makes the product FDA-approved. FDA says plainly that compounded drugs are not FDA-approved, and that it does not verify their safety, effectiveness or quality before they are marketed.
For the wider background, start with the compounded GLP-1 overview.
503A: state-licensed pharmacies and physicians
A 503A compounder is a licensed pharmacist in a state-licensed pharmacy or federal facility, or a physician. Here is how FDA describes the main features.
- Who oversees it. “Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities.” FDA does carry out surveillance and for-cause inspections of these pharmacies, meaning inspections prompted by a specific problem.
- A prescription is required. Under section 503A, “the drug product is compounded for an individual patient based on receipt of a prescription.”
- Quality standard. Drugs compounded under the conditions of section 503A are not subject to current good manufacturing practice (CGMP) requirements. CGMP is the set of federal manufacturing quality rules.
- Reporting side effects. FDA notes that federal law does not require state-licensed pharmacies that are not outsourcing facilities to send adverse events to FDA. That’s one reason FDA believes adverse events from compounded GLP-1 drugs are underreported.
503B: outsourcing facilities
Outsourcing facilities are a newer category. FDA describes them as “a category of compounders established in 2013 by the Drug Quality and Security Act.”
- Who oversees it. Facilities that register with FDA as outsourcing facilities under section 503B “are primarily overseen by FDA and inspected by FDA according to a risk-based schedule.”
- Quality standard. “Drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements.” FDA says outsourcing facilities are held to higher quality standards.
- Who does the compounding. In an outsourcing facility, a person under the supervision of a licensed pharmacist does the compounding.
Registered doesn’t mean approved. Among the claims FDA says telehealth companies must not make is that a compounded drug comes from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. FDA’s reason is short: “FDA does not approve or license any facility.”
The copy rule works differently under each section
Both sections limit compounding of drugs that are essentially copies of approved products. The tests are different.
Under 503A, the compounder may not compound “regularly or in inordinate amounts” drugs that are essentially copies of a commercially available drug product. FDA explains: “When a drug shortage is resolved, FDA generally considers the drug to be commercially available. Certain amounts are permissible under the law as long as the compounding is not done ‘regularly or in inordinate amounts.’” FDA has said that, at this time, it does not intend to act if the compounder fills four or fewer prescriptions of that compounded product in a calendar month.
Adding a second ingredient doesn’t settle the question. FDA’s example is a product that combines semaglutide with vitamin B12. FDA may consider it essentially a copy when it’s used by the same route (the way the drug is given, such as by injection) and the amounts of semaglutide and vitamin B12 are within 10% of the strengths of the matching commercially available products.
Under 503B, the limit is tighter. FDA says the section “restricts outsourcing facilities from making compounded drugs that are essentially a copy of one or more FDA-approved drugs.” That means the compounded drug “may not be identical or nearly identical to an FDA-approved drug unless the approved drug is on FDA’s drug shortage list.”
The bulk substance rule applies to 503B
Outsourcing facilities face a second limit, on what they may start from. They may not compound with a bulk drug substance (the active pharmaceutical ingredient in raw form) unless one of these is true:
- the substance appears on the 503B bulks list, a list of substances for which FDA has found a clinical need, or
- the drug made from it is on FDA’s drug shortage list at the time of compounding, distribution and dispensing.
FDA has said where the GLP-1 substances stand: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”
How the shortage wind-down treated each type
When FDA declared each shortage resolved, it gave the two types of compounder different amounts of time to wind down.
- Tirzepatide (decision of December 19, 2024): 60 calendar days for 503A state-licensed pharmacies, until February 18, 2025, and 90 calendar days for 503B outsourcing facilities, until March 19, 2025.
- Semaglutide (decision of February 21, 2025): 60 calendar days for 503A pharmacies and physicians, until April 22, 2025, and 90 calendar days for 503B outsourcing facilities, until May 22, 2025.
Those periods are over. The overview page covers the court rulings that followed.
The 2026 proposal on the 503B bulks list
On May 1, 2026, FDA published a Federal Register notice naming three bulk drug substances it “has considered and proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide.” FDA wrote that it tentatively finds no basis to conclude there is a clinical need for an outsourcing facility to compound using them. It added that it does not consider shortages and backorders to fall within the meaning of clinical need.
The law sets three steps. First, a Federal Register notice proposing FDA’s position and its reasons. Second, a comment period of not less than 60 calendar days. Third, a further Federal Register notice with the final decision.
The dates:
- The May 1, 2026 notice set a comment deadline of June 30, 2026. FDA’s own press release gave June 29, 2026.
- A notice published on June 26, 2026 extended the comment period to July 30, 2026, after a request for more time. The docket number is FDA-2018-N-3240.
A proposal becomes final only when FDA publishes that further notice. The docket is where you can confirm whether it has.
What this means if you’re a patient
- The section number is not a quality grade. 503B facilities meet CGMP requirements and 503A pharmacies don’t have to. In both cases, FDA has not reviewed the finished product.
- A 503A product needs a prescription written for you. A product offered without one doesn’t meet the section’s first condition.
- Ask where the product is made. FDA’s warning letters in 2026 cited websites that hid the source by implying the telehealth company was the compounder. The pharmacy verification page explains how to look up a license.
- Take your questions to a professional. Your prescriber or pharmacist can tell you whether an FDA-approved medicine meets your needs. That’s the test FDA applies to compounding in the first place. The cost guide lists the prices of the approved medicines.
Frequently asked questions
Is a 503B pharmacy FDA-approved?
No. A 503B outsourcing facility registers with FDA and is inspected by FDA on a risk-based schedule, meaning higher-risk sites get checked more often. But FDA says it does not approve or license any facility. The drugs made there are compounded drugs, and FDA says compounded drugs are not FDA-approved. Being registered and inspected is not the same as having a product approved.
Does a 503A pharmacy need a prescription to compound a GLP-1?
Yes. FDA says that under section 503A the drug product is compounded for an individual patient based on receipt of a prescription. The same section bars the compounder from regularly, or in inordinate amounts, compounding drugs that are essentially copies of a commercially available drug product.
Can 503B facilities still make compounded semaglutide or tirzepatide?
FDA says outsourcing facilities may not compound from a bulk drug substance unless it appears on the 503B bulks list, or the drug is on the shortage list at the time of compounding, distribution and dispensing. FDA has said that tirzepatide and semaglutide appear on neither list.
What is the four-prescription threshold FDA mentions?
It's a statement about enforcement for 503A compounders, not a safety standard. FDA has said that, at this time, it does not intend to act against a compounder for compounding an essential copy of a commercially available drug regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded product in a calendar month.
Has FDA made a final decision on the 503B bulks list for GLP-1s?
Not in the notices this page covers, which are a proposal and an extension. FDA proposed on May 1, 2026 not to include semaglutide, tirzepatide and liraglutide on the 503B Bulks List, then extended the comment period to July 30, 2026. By law, the list is set by a further Federal Register notice after the comment period ends.
Sources (18)
- 1.FDA: Compounding and the FDA: Questions and Answers
“Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities. FDA does conduct surveillance and for-cause inspections of state-licensed pharmacies that are not registered as outsourcing facilities.”
- 2.FDA: Compounding and the FDA: Questions and Answers
“Outsourcing facilities are a category of compounders established in 2013 by the Drug Quality and Security Act. Outsourcing facilities are inspected by FDA according to a risk-based schedule and are subject to increased quality standards. [...] Facilities that register with FDA as outsourcing facilities under section 503B are primarily overseen by FDA and inspected by FDA according to a risk-based schedule.”
- 3.FDA: Compounding and the FDA: Questions and Answers
“Quality standards for compounded drugs differ depending on the setting where compounding occurs. Drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements. By contrast, drugs compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician, in accordance with the conditions of section 503A of the FD&C Act, are not.”
- 4.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“Under section 503A: The drug product is compounded for an individual patient based on receipt of a prescription. The compounder does not compound, regularly or in inordinate amounts, any that are essentially copies of a commercially available drug product.”
- 5.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“For example, FDA may consider a compounded drug product that combines semaglutide API and another API, such as vitamin B12 (cyanocobalamin), to be essentially a copy of a commercially available drug product when the: drug products are used by the same route of administration – the compounded drug product is given the same way as the commercially available drug products, such as an injectable drug products are the same, similar or easily substitutable strength – the amounts of semaglutide and vitamin B12 in the compounded drug product are within 10% of the strengths of the respective commercially available drug products.”
- 6.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“FDA has stated, at this time, it does not intend to take action against a compounder for compounding a drug product that is essentially a copy of a commercially available drug product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month.”
- 7.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“Outsourcing facilities are restricted from compounding drugs using bulk drug substances (or API) unless: the bulk drug substance appears on a list identifying bulk drug substances for which there is a clinical need, which is referred to as the 503B bulks list or the drug compounded from the bulk drug substance is on FDA’s drug shortage list at the time of compounding, distribution and dispensing. Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”
- 8.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“Section 503A of the FD&C Act includes restrictions on compounding drugs that are essentially copies of a commercially available drug. When a drug shortage is resolved, FDA generally considers the drug to be commercially available. Certain amounts are permissible under the law as long as the compounding is not done “regularly or in inordinate amounts.” Section 503B of the FD&C Act restricts outsourcing facilities from making compounded drugs that are essentially a copy of one or more FDA-approved drugs. Among other things, this means the compounded drug may not be identical or nearly identical to an FDA-approved drug unless the approved drug is on FDA’s drug shortage list.”
- 9.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“FDA re-evaluated its determination from October 2, 2024, on the status of the tirzepatide shortage. Today, FDA has issued a new decision determining the tirzepatide injection shortage is resolved. [...] For a state-licensed pharmacy under section 503A of the FD&C Act compounding, distributing or dispensing tirzepatide injections within 60 calendar days from today’s announcement, until February 18, 2025. For outsourcing facilities under section 503B compounding, distributing or dispensing tirzepatide injections within 90 calendar days from today’s announcement, until March 19, 2025.”
- 10.FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
“FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Semaglutide injection products have been in shortage since 2022 due to increased demand. [...] For a state-licensed pharmacy or physician compounding under section 503A of the FD&C Act: compounding, distributing or dispensing semaglutide injection products that are essentially a copy of an FDA-approved product within 60 calendar days from today’s announcement, until April 22, 2025. For outsourcing facilities under section 503B of the FD&C Act: compounding, distributing or dispensing semaglutide injection products that are essentially a copy of an FDA-approved drug product within 90 calendar days from today’s announcement, until May 22, 2025.”
- 11.Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
“The Food and Drug Administration (FDA, the Agency, or we) is evaluating substances that have been nominated for inclusion on a list of bulk drug substances (active pharmaceutical ingredients) for which there is a clinical need for outsourcing facilities to use in compounding (the 503B Bulks List). This notice identifies three bulk drug substances that FDA has considered and proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide.”
- 12.Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
“For the reasons stated above, FDA tentatively finds no basis to conclude that there is a clinical need for an outsourcing facility to compound using the following bulk drug substances: semaglutide, tirzepatide, and liraglutide. Therefore, we propose not to include these bulk drug substances on the 503B Bulks List. [...] However, FDA does not interpret such issues, such as shortages and backorders, to be within the meaning of “clinical need” for compounding with a bulk drug substance.”
- 13.Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
“Either electronic or written comments on the notice must be submitted by June 30, 2026. [also: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list] The FDA is now inviting interested parties to submit comments electronically through the docket by June 29, 2026. The agency will consider submitted comments before making a final determination.”
- 14.Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
“The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice entitled “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act” that appeared in the Federal Register of May 1, 2026. [...] The Agency is taking this action in response to a request for an extension to allow interested persons additional time to submit comments. [...] FDA is extending the comment period on the notice published in the Federal Register of May 1, 2026 (91 FR 23431). Either electronic or written comments must be submitted by July 30, 2026.”
- 15.Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
“Section 503B of the FD&C Act directs FDA to establish the 503B Bulks List by: (1) publishing a notice in the Federal Register proposing bulk drug substances to be included on the list, including the rationale for such proposal; (2) providing a period of not less than 60 calendar days for comment on the notice; and (3) publishing a notice in the Federal Register designating bulk drug substances for inclusion on the list.”
- 16.FDA: Compounding and the FDA: Questions and Answers
“Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. Consumers and health care professionals rely on FDA’s drug approval process for verification of safety, effectiveness and quality.”
- 17.FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
“However, federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported. [...] As of May 31, 2026, the FDA has received: 990 reports of adverse events associated with compounded semaglutide. more than 730 reports of adverse events associated with compounded tirzepatide. It is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed to these adverse events.”
- 18.FDA: FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs
“The agency reminds telehealth companies not to market compounded GLP-1 drugs to consumers with false or misleading claims, including: using branding on their website that falsely or misleadingly implies the telehealth company is the compounder. describing a compounded drug as a generic version of an FDA-approved drug or the same as a drug approved by FDA. Generic drugs are approved by FDA prior to marketing, while a compounded drug is not approved by FDA. claiming a compounded drug has been FDA-approved or has otherwise been evaluated for safety and effectiveness when they are not. Compounded drugs are not reviewed by the agency for safety, effectiveness or quality prior to marketing. describing a compounded drug as clinically proven to produce the same result as the FDA-approved drug. claiming a compounded drug is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. FDA does not approve or license any facility.”
